CTLA4 and melanoma: Checkpoint inhibitors nivolumab, an anti-programmed death-1 (PD-1) antibody, and ipilimumab, an anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody, demonstrated increased survival in untreated melanoma (10) and were FDA approved in 2015.